Rapid Itch Relief and Quality-of-Life With Next-Generation Oral TYK2 Inhibitors in Psoriasis

In this Dermatology Times Expert Perspectives episode, April Armstrong, MD, MPH, highlights the clinical importance of pruritus as a primary driver of disease burden in patients with moderate to severe plaque psoriasis and explores how emerging oral therapies are reshaping symptom management. Armstrong emphasizes that itch in psoriasis is both qualitatively and clinically distinct from other inflammatory dermatoses and remains a key determinant of patient-reported quality of life.

Focusing on recent phase 3 data, Armstrong discusses the rapid antipruritic effects observed with envudeucitinib. Notably, patients demonstrated meaningful reductions in itch as early as week 2, preceding visible improvements in skin clearance. This early symptomatic relief may play a critical role in treatment adherence and patient confidence, particularly in systemic-naïve populations or those with high baseline symptom burden.

Beyond symptom control, the episode examines patient-reported outcomes presented in late-breaking sessions at the 2026 American Academy of Dermatology Annual Meeting. Approximately 50% of patients with significant baseline impairment achieved Dermatology Life Quality Index (DLQI) scores of 0 or 1 by week 12, indicating minimal to no impact of psoriasis on daily functioning. These findings reinforce the broader therapeutic goal of not only achieving skin clearance but also normalizing quality of life.

Armstrong further contextualizes these data within the expanding oral treatment landscape, including the recent approval of icotrokinra and the emergence of additional next-generation TYK2 inhibitors such as zasocitinib. Consistency in efficacy and safety outcomes across this class strengthens confidence in TYK2 as a central therapeutic target.

Collectively, these advances signal enhancements in psoriasis care, where oral agents may increasingly deliver rapid symptom relief, robust efficacy, and meaningful quality-of-life improvements, offering clinicians greater flexibility in individualized treatment selection.

View the full series here.